{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:10:58Z","timestamp":1771830658563,"version":"3.50.1"},"reference-count":44,"publisher":"Jaypee Brothers Medical Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.59556\/japi.74.1372","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:43:07Z","timestamp":1771828987000},"page":"38-46","source":"Crossref","is-referenced-by-count":0,"title":["Drug Resistance in HIV Following First-line ART Failure: Insights from a Cross-sectional Study in India"],"prefix":"10.59556","volume":"74","author":[{"given":"Sumit","family":"Arora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pogatyanatti","family":"Basavaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuldeep Kumar","family":"Ashta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anirudh","family":"Anil kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishant","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"key":"key20260223064257_B1","doi-asserted-by":"crossref","first-page":"1\u2013","DOI":"10.1097\/COH.0000000000000710","article-title":"Editorial: new drugs for HIV: quo vadis?","volume":"17:","author":"Flexner","year":"2022;","journal-title":"Curr Opin HIV AIDS"},{"key":"key20260223064257_B2","doi-asserted-by":"crossref","first-page":"143\u2013","DOI":"10.1097\/COH.0000000000000527","article-title":"Current and future priorities for the development of optimal HIV drugs.","volume":"14:","author":"Vitoria","year":"2019;","journal-title":"Curr Opin HIV AIDS"},{"key":"key20260223064257_B3","first-page":"28.","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis.","author":"Kanters","year":"2020;","journal-title":"EClinicalMedicine"},{"issue":"(19):","key":"key20260223064257_B4","first-page":"E25763.","article-title":"Durability of non-nucleotide reverse transcriptase inhibitor-based first-line ART regimens after 7 years of treatment in rural Uganda: a prospective cohort study.","volume":"100","author":"Nanfuka","year":"2021;","journal-title":"Med (United States)"},{"issue":"(9927):","key":"key20260223064257_B5","first-page":"1474\u2013","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.","volume":"383","author":"Amin","year":"2014;","journal-title":"Lancet"},{"key":"key20260223064257_B6","doi-asserted-by":"crossref","first-page":"973771.","DOI":"10.3389\/fmicb.2022.973771","article-title":"High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; a 2017 study.","volume":"13:","author":"Parbie","year":"2022;","journal-title":"Front Microbiol"},{"key":"key20260223064257_B7","unstructured":"World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens [Internet]. WHO; 2019. Available from: http:\/\/www.who.int\/hiv\/pub\/arv\/arv-update-2019-policy\/en\/"},{"issue":"(4):","key":"key20260223064257_B8","doi-asserted-by":"crossref","first-page":"330\u2013","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV.","volume":"385","author":"Paton","year":"2021;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20260223064257_B9","first-page":"1\u2013","article-title":"Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.","volume":"20","author":"Rhee","year":"2023;","journal-title":"AIDS Res Ther"},{"issue":"(5):","key":"key20260223064257_B10","doi-asserted-by":"crossref","first-page":"e25706.","DOI":"10.1002\/jia2.25706","article-title":"Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.","volume":"24","author":"Steegen","year":"2021;","journal-title":"J Int AIDS Soc"},{"issue":"(6).","key":"key20260223064257_B11","article-title":"Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV\/r) and\/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.","volume":"25","author":"Avihingsanon","year":"2022;","journal-title":"J Int AIDS Soc"},{"issue":"(1).","key":"key20260223064257_B12","article-title":"The role of rilpivirine in Southern Africa.","volume":"20","author":"Moorhouse","year":"2019;","journal-title":"South Afr J HIV Med"},{"issue":"(1):","key":"key20260223064257_B13","doi-asserted-by":"crossref","first-page":"210\u2013","DOI":"10.1093\/jac\/dkw358","article-title":"HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.","volume":"72","author":"Steegen","year":"2017;","journal-title":"J Antimicrob Chemother"},{"issue":"(6):","key":"key20260223064257_B14","doi-asserted-by":"crossref","first-page":"1009\u2013","DOI":"10.1097\/QAD.0000000000003505","article-title":"Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries.","volume":"37","author":"Steegen","year":"2023;","journal-title":"AIDS"},{"key":"key20260223064257_B15","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.","author":"World Health Organization.","year":"2016."},{"key":"key20260223064257_B16","unstructured":"National AIDS Control Organization; Ministry of Health and Family Welfare; Government of India. National technical guidelines on antiretroviral treatment [Internet]. 2018. Available from: https:\/\/naco.gov.in\/sites\/default\/files\/NACO%20-%20National%20Technical%20Guidelines%20on%20ART_October%202018.pdf"},{"key":"key20260223064257_B17","doi-asserted-by":"crossref","unstructured":"Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004\u20132011 [Internet]. Clin Infect Dis. 2012;54:S245 [cited 2024 Jul 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3338313\/","DOI":"10.1093\/cid\/cis206"},{"key":"key20260223064257_B18","doi-asserted-by":"crossref","first-page":"15\u2013","DOI":"10.1177\/135965350801302S07","article-title":"World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.","volume":"13:","author":"Jordan","year":"2008;","journal-title":"Antiviral Ther"},{"key":"key20260223064257_B19","unstructured":"Stanford Database (HIVdb). HIV drug resistance database, version 9.1 update 2022-06-02 [Internet]. 2022 [cited 2022 Oct 7]. Available from: https:\/\/hivdb.stanford.edu\/"},{"key":"key20260223064257_B20","volume-title":"HIV drug resistance: WHO\/HIVResNet HIV drug resistance laboratory operational framework,","author":"World Health Organization.","year":"2020.","edition":"2nd edition."},{"issue":"(Suppl 2).","key":"key20260223064257_B21","article-title":"Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.","volume":"207","author":"Hosseinipour","year":"2013;","journal-title":"J Infect Dis"},{"issue":"(9):","key":"key20260223064257_B22","doi-asserted-by":"crossref","first-page":"e620\u2013","DOI":"10.1016\/S2352-3018(20)30172-7","article-title":"Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study.","volume":"7","author":"Gupta-Wright","year":"2020;","journal-title":"Lancet HIV"},{"issue":"(4):","key":"key20260223064257_B23","doi-asserted-by":"crossref","first-page":"291\u2013","DOI":"10.3851\/IMP3299","article-title":"Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia.","volume":"24","author":"Parker Hudson","year":"2019;","journal-title":"Antivir Ther"},{"key":"key20260223064257_B24","doi-asserted-by":"crossref","first-page":"468\u2013","DOI":"10.1016\/j.jgar.2021.10.023","article-title":"HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa.","volume":"29:","author":"Chimukangara","year":"2022;","journal-title":"J Glob Antimicrob Resist"},{"issue":"(5):","key":"key20260223064257_B25","doi-asserted-by":"crossref","first-page":"565\u2013","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.","volume":"16","author":"Gregson","year":"2016;","journal-title":"Lancet Infect Dis"},{"issue":"(12):","key":"key20260223064257_B26","doi-asserted-by":"crossref","first-page":"1234\u2013","DOI":"10.1089\/aid.2016.0110","article-title":"Genotypic HIV-1 drug resistance among patients failing tenofovir-based first-line HAART in South India.","volume":"32","author":"Dinesha","year":"2016;","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"(1):","key":"key20260223064257_B27","doi-asserted-by":"crossref","first-page":"74.","DOI":"10.1186\/s12981-021-00393-5","article-title":"Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa.","volume":"18","author":"Chimukangara","year":"2021;","journal-title":"AIDS Res Ther"},{"key":"key20260223064257_B28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236156","article-title":"Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.","volume":"15.","author":"Miti","year":"2020;","journal-title":"PLoS One"},{"issue":"(3):","key":"key20260223064257_B29","doi-asserted-by":"crossref","first-page":"296\u2013","DOI":"10.1016\/S1473-3099(16)30469-8","article-title":"Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub-Saharan Africa: a retrospective multi-centre cohort study.","volume":"17","author":"Gregson","year":"2017;","journal-title":"Lancet Infect Dis"},{"issue":"(2):","key":"key20260223064257_B30","doi-asserted-by":"crossref","first-page":"228\u2013","DOI":"10.1089\/aid.2017.0198","article-title":"Distinct pattern of thymidine analogue mutations with K65R in patients failing tenofovir-based antiretroviral therapy.","volume":"34","author":"Chaplin","year":"2018;","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"(10).","key":"key20260223064257_B31","article-title":"Antiretroviral drug resistance in HIV sequences from people who inject drugs and men who have sex with men across 21 cities in India.","volume":"9","author":"Clipman","year":"2022;","journal-title":"Open Forum Infect Dis"},{"issue":"(1):","key":"key20260223064257_B32","doi-asserted-by":"crossref","first-page":"27\u2013","DOI":"10.1016\/j.inhe.2010.11.003","article-title":"Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.","volume":"3","author":"Ekstrand","year":"2011;","journal-title":"Int Health"},{"key":"key20260223064257_B33","doi-asserted-by":"crossref","DOI":"10.1177\/13596535231201162","article-title":"HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective.","volume":"28.","author":"Carr","year":"2023;","journal-title":"Antiviral Ther"},{"key":"key20260223064257_B34","unstructured":"Mackie N. Resistance to non-nucleoside reverse transcriptase inhibitors [Internet]. In: Antiretroviral Resistance in Clinical Practice. 2006 [cited 2023 Oct 21]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK2249\/"},{"key":"key20260223064257_B35","first-page":"2021.","article-title":"High detection rate of HIV drug resistance mutations among patients who fail combined antiretroviral therapy in Manaus, Brazil.","author":"Chaves","year":"2021;","journal-title":"Biomed Res Int"},{"issue":"(28).","key":"key20260223064257_B36","article-title":"Treatment outcomes and HIV drug resistance of patients switching to second-line regimens after long-term first-line antiretroviral therapy: an observational cohort study.","volume":"97","author":"Cao","year":"2018;","journal-title":"Med (United States)"},{"key":"key20260223064257_B37","doi-asserted-by":"crossref","first-page":"33\u2013","DOI":"10.1016\/j.ijid.2017.10.020","article-title":"HIV drug resistance following a decade of the free antiretroviral therapy programme in India: a review.","volume":"66:","author":"Karade","year":"2018;","journal-title":"Int J Infect Dis"},{"issue":"(4):","key":"key20260223064257_B38","doi-asserted-by":"crossref","first-page":"258\u2013","DOI":"10.5114\/hivar.2017.72027","article-title":"Emergence of HIV drug-resistant mutations in East Indian population after failure of first-line antiretroviral therapy.","volume":"16","author":"Dutta","year":"2017;","journal-title":"HIV AIDS Rev"},{"issue":"(10):","key":"key20260223064257_B39","first-page":"611\u2013","article-title":"Successful switch to rilpivirine\/tenofovir\/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.","volume":"15","author":"Verbon","year":"2014;","journal-title":"HIV Med"},{"issue":"(8):","key":"key20260223064257_B40","doi-asserted-by":"crossref","first-page":"667.","DOI":"10.1089\/aid.2017.0135","article-title":"Prevalence of rilpivirine and etravirine resistance mutations in HIV-1 subtype C-infected patients failing nevirapine or efavirenz-based combination antiretroviral therapy in Botswana.","volume":"34","author":"Diphoko","year":"2018;","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"(6):","key":"key20260223064257_B41","doi-asserted-by":"crossref","first-page":"e324\u2013","DOI":"10.1016\/S2352-3018(21)00021-7","article-title":"Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.","volume":"8","author":"Molina","year":"2021;","journal-title":"Lancet HIV"},{"key":"key20260223064257_B42","first-page":"201\u2013","article-title":"Doravirine and its potential in the treatment of HIV: an evidence-based review of the emerging data.","volume":"12:","author":"Rock","year":"2020;","journal-title":"HIV AIDS (Auckl)"},{"issue":"(4):","key":"key20260223064257_B43","doi-asserted-by":"crossref","first-page":"1026\u2013","DOI":"10.1093\/jac\/dkz553","article-title":"Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.","volume":"75","author":"Soulie","year":"2020;","journal-title":"J Antimicrob Chemother"},{"issue":"(4):","key":"key20260223064257_B44","doi-asserted-by":"crossref","first-page":"515\u2013","DOI":"10.1016\/j.ijantimicag.2019.02.007","article-title":"Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.","volume":"53","author":"Sterrantino","year":"2019;","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:43:14Z","timestamp":1771828994000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-2-38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.59556\/japi.74.1372"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1372","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}